{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T01:18:03Z","timestamp":1789089483811,"version":"build-2803163510"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T00:00:00Z","timestamp":1749686400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T00:00:00Z","timestamp":1749686400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Takeda Development Center Americas Inc"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s12325-025-03226-3","type":"journal-article","created":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T00:58:55Z","timestamp":1749689935000},"page":"3882-3901","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Sustained Effectiveness, Tolerability, and Safety of Long-Term Prophylaxis with Lanadelumab in Hereditary Angioedema: The\u00a0Prospective, Phase\u00a04, Noninterventional EMPOWER Real-World Study"],"prefix":"10.1007","volume":"42","clinical-trial-number":[{"clinical-trial-number":"nct03845400","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Jonathan A.","family":"Bernstein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen D.","family":"Betschel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula J.","family":"Busse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleena","family":"Banerji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8428-6568","authenticated-orcid":false,"given":"H. James","family":"Wedner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4455-7356","authenticated-orcid":false,"given":"Michael","family":"Manning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael H.","family":"Zaragoza-Urdaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3578-8064","authenticated-orcid":false,"given":"John","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remi","family":"Gagnon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8284-0027","authenticated-orcid":false,"given":"Alan P.","family":"Baptist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Soteres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7608-5416","authenticated-orcid":false,"given":"William R.","family":"Lumry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7774-4855","authenticated-orcid":false,"given":"Timothy","family":"Craig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Petroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2201-9442","authenticated-orcid":false,"given":"F. Ida","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Nova Estepan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salom\u00e9","family":"Juethner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen","family":"Watt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Khutoryansky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce L.","family":"Zuraw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the EMPOWER Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan P","family":"Baptist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula J","family":"Busse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo","family":"Chapdelaine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selina","family":"Gierer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Dawn","family":"Goodyear","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Kashkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul K.","family":"Keith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Henry","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Lockey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Lugar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Raasch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffi","family":"Tachdjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Weinstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,12]]},"reference":[{"key":"3226_CR1","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/j.anai.2023.08.012","volume":"131","author":"SC Christiansen","year":"2023","unstructured":"Christiansen SC, Wilmot J, Castaldo AJ, Zuraw BL. The US Hereditary Angioedema Association Scientific Registry: hereditary angioedema demographics, disease severity, and comorbidities. Ann Allergy Asthma Immunol. 2023;131:766\u201374.e8.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"3226_CR2","first-page":"S292","volume":"24","author":"JA Bernstein","year":"2018","unstructured":"Bernstein JA. Severity of hereditary angioedema, prevalence, and diagnostic considerations. Am J Manag Care. 2018;24:S292\u20138.","journal-title":"Am J Manag Care"},{"key":"3226_CR3","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1111\/all.15214","volume":"77","author":"M Maurer","year":"2022","unstructured":"Maurer M, Magerl M, Betschel S, et al. The international WAO\/EAACI guideline for the management of hereditary angioedema\u2014the 2021 revision and update. Allergy. 2022;77:1961\u201390.","journal-title":"Allergy"},{"key":"3226_CR4","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.jaip.2020.08.046","volume":"9","author":"PJ Busse","year":"2021","unstructured":"Busse PJ, Christiansen SC, Riedl MA, et al. US HAEA Medical Advisory Board 2020 guidelines for the management of hereditary angioedema. J Allergy Clin Immunol Pract. 2021;9:132\u201350.e3.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"3226_CR5","doi-asserted-by":"publisher","first-page":"212","DOI":"10.3389\/fmed.2017.00212","volume":"4","author":"A Bygum","year":"2017","unstructured":"Bygum A, Busse P, Caballero T, Maurer M. Disease severity, activity, impact, and control and how to assess them in patients with hereditary angioedema. Front Med (Lausanne). 2017;4:212.","journal-title":"Front Med (Lausanne)"},{"key":"3226_CR6","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13223-021-00537-2","volume":"17","author":"K Bork","year":"2021","unstructured":"Bork K, Anderson JT, Caballero T, et al. Assessment and management of disease burden and quality of life in patients with hereditary angioedema: a consensus report. Allergy Asthma Clin Immunol. 2021;17:40.","journal-title":"Allergy Asthma Clin Immunol"},{"key":"3226_CR7","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s13023-021-01717-4","volume":"16","author":"J Mendivil","year":"2021","unstructured":"Mendivil J, Murphy R, de la Cruz M, et al. Clinical characteristics and burden of illness in patients with hereditary angioedema: findings from a multinational patient survey. Orphanet J Rare Dis. 2021;16:94.","journal-title":"Orphanet J Rare Dis"},{"key":"3226_CR8","doi-asserted-by":"publisher","DOI":"10.1002\/clt2.12243","volume":"13","author":"AS Grumach","year":"2023","unstructured":"Grumach AS, Gadir N, Kessel A, Yegin A, Martinez-Saguer I, Bernstein JA. Current challenges and future opportunities in patient-focused management of hereditary angioedema: a narrative review. Clin Transl Allergy. 2023;13:e12243.","journal-title":"Clin Transl Allergy"},{"key":"3226_CR9","doi-asserted-by":"publisher","first-page":"23596","DOI":"10.1074\/jbc.M114.569061","volume":"289","author":"JA Kenniston","year":"2014","unstructured":"Kenniston JA, Faucette RR, Martik D, et al. Inhibition of plasma kallikrein by a highly specific active site blocking antibody. J Biol Chem. 2014;289:23596\u2013608.","journal-title":"J Biol Chem"},{"key":"3226_CR10","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.anai.2014.05.028","volume":"113","author":"Y Chyung","year":"2014","unstructured":"Chyung Y, Vince B, Iarrobino R, et al. A phase\u00a01 study investigating DX-2930 in healthy subjects. Ann Allergy Asthma Immunol. 2014;113:460\u20136.e2.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"3226_CR11","unstructured":"Takeda Pharmaceuticals U.S.A. Inc. Highlights of prescribing information. TAKHZYRO\u00ae (lanadelumab-flyo) injection, for subcutaneous use. 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761090s010lbl.pdf. Accessed 27 Nov 2023."},{"key":"3226_CR12","unstructured":"Takeda Pharmaceuticals International AG. Summary of product characteristics. TAKHZYRO\u00ae (INN-lanadelumab). 2025. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/takhzyro-epar-product-information_en.pdf. Accessed 7 Apr 2025."},{"key":"3226_CR13","unstructured":"Takeda Canada Inc. Product monograph including patient medication information. TAKHZYRO\u00ae (lanadelumab injection). 2021. https:\/\/pdf.hres.ca\/dpd_pm\/00060484.PDF. Accessed 7 Apr 2025."},{"key":"3226_CR14","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1001\/jama.2018.16773","volume":"320","author":"A Banerji","year":"2018","unstructured":"Banerji A, Riedl MA, Bernstein JA, et al. Effect of lanadelumab compared with placebo on prevention of hereditary angioedema attacks: a randomized clinical trial. JAMA. 2018;320:2108\u201321.","journal-title":"JAMA"},{"issue":"201\u201311","key":"3226_CR15","volume":"12","author":"M Maurer","year":"2024","unstructured":"Maurer M, Lumry WR, Li HH, et al. Lanadelumab in patients 2 to less than 12\u00a0years old with hereditary angioedema: results from the phase\u00a03 SPRING Study. J Allergy Clin Immunol Pract. 2024;12:201\u201311.e6.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"3226_CR16","unstructured":"Takeda Pharmaceuticals U.S.A. Inc. Freedom from daily dosing. https:\/\/www.takhzyro.com\/how-to-take. Accessed 3 Mar 2024."},{"key":"3226_CR17","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1111\/all.14416","volume":"75","author":"MA Riedl","year":"2020","unstructured":"Riedl MA, Maurer M, Bernstein JA, et al. Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks. Allergy. 2020;75:2879\u201387.","journal-title":"Allergy"},{"key":"3226_CR18","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1111\/all.15011","volume":"77","author":"A Banerji","year":"2022","unstructured":"Banerji A, Bernstein JA, Johnston DT, et al. Long-term prevention of hereditary angioedema attacks with lanadelumab: the HELP OLE Study. Allergy. 2022;77:979\u201390.","journal-title":"Allergy"},{"key":"3226_CR19","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s13223-021-00579-6","volume":"17","author":"A Iaboni","year":"2021","unstructured":"Iaboni A, Kanani A, Lacuesta G, Song C, Kan M, Betschel SD. Impact of lanadelumab in hereditary angioedema: a case series of 12 patients in Canada. Allergy Asthma Clin Immunol. 2021;17:78.","journal-title":"Allergy Asthma Clin Immunol"},{"key":"3226_CR20","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s13223-022-00664-4","volume":"18","author":"O Fain","year":"2022","unstructured":"Fain O, Du-Thanh A, Gobert D, et al. Long-term prophylaxis with lanadelumab for HAE: authorization for temporary use in France. Allergy Asthma Clin Immunol. 2022;18:30.","journal-title":"Allergy Asthma Clin Immunol"},{"key":"3226_CR21","doi-asserted-by":"publisher","first-page":"91","DOI":"10.5415\/apallergy.0000000000000102","volume":"13","author":"AG Bernardino","year":"2023","unstructured":"Bernardino AG, Ferreira MB, Costa C, Caiado J, Pedro E, Santos AS. Experience of lanadelumab administration in hereditary angioedema: a case series of 4 patients in Portugal. Asia Pac Allergy. 2023;13:91\u20134.","journal-title":"Asia Pac Allergy"},{"key":"3226_CR22","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1111\/all.15620","volume":"78","author":"AD Dorr","year":"2023","unstructured":"Dorr AD, Chopra C, Coulter TI, et al. Lanadelumab for the prevention of hereditary angioedema attacks: a real-world UK audit. Allergy. 2023;78:1369\u201371.","journal-title":"Allergy"},{"key":"3226_CR23","doi-asserted-by":"publisher","DOI":"10.1111\/pai.70072","volume":"36","author":"R Tachdjian","year":"2025","unstructured":"Tachdjian R, Banerji A, Busse PJ, et al. Effective long-term prophylaxis with lanadelumab in adolescents with hereditary angioedema: EMPOWER\/ENABLE. Pediatr Allergy Immunol. 2025;36:e70072.","journal-title":"Pediatr Allergy Immunol"},{"issue":"712\u20139","key":"3226_CR24","volume":"133","author":"T Craig","year":"2024","unstructured":"Craig T, Tachdjian R, Bernstein JA, et al. Long-term prevention of hereditary angioedema attacks with lanadelumab in adolescents. Ann Allergy Asthma Immunol. 2024;133:712\u20139.e1.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"3226_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.waojou.2022.100664","volume":"15","author":"M Abuzakouk","year":"2022","unstructured":"Abuzakouk M, Ghorab O, Al-Hameli H, Salvo F, Grandon D, Maurer M. Using an extended treatment regimen of lanadelumab in the prophylaxis of hereditary angioedema: a single-centre experience. World Allergy Organ J. 2022;15:100664.","journal-title":"World Allergy Organ J"},{"key":"3226_CR26","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1111\/ddg.14785","volume":"20","author":"I Martinez-Saguer","year":"2022","unstructured":"Martinez-Saguer I, Knop J, Flemming A, Thomann M, Maurer M. Real world treatment patterns of hereditary angioedema with lanadelumab in Germany: a prescription data analysis. J Dtsch Dermatol Ges. 2022;20:1127\u20139.","journal-title":"J Dtsch Dermatol Ges"},{"key":"3226_CR27","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1080\/13696998.2023.2232260","volume":"26","author":"CH Shah","year":"2023","unstructured":"Shah CH, Princic N, Evans KA, Schultz BG. Real-world changes in costs over time among patients in the United States with hereditary angioedema on long-term prophylaxis with lanadelumab. J Med Econ. 2023;26:871\u20137.","journal-title":"J Med Econ"},{"key":"3226_CR28","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1093\/jamia\/ocaa036","volume":"27","author":"M Milne-Ives","year":"2020","unstructured":"Milne-Ives M, van Velthoven MH, Meinert E. Mobile apps for real-world evidence in health care. J Am Med Inform Assoc. 2020;27:976\u201380.","journal-title":"J Am Med Inform Assoc"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03226-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03226-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03226-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T19:24:27Z","timestamp":1757186667000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03226-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,12]]},"references-count":28,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["3226"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03226-3","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,12]]},"assertion":[{"value":"20 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Jonathan A. Bernstein has been or is currently a clinical investigator for BioCryst, BioMarin Pharmaceutical, CSL Behring, Ionis, KalVista Pharmaceuticals, Pharming Group, and Takeda; consultant for BioCryst, BioMarin Pharmaceutical, CSL Behring, Ionis, KalVista Pharmaceuticals, Pharming Group, and Takeda; and a member of the Hereditary Angioedema Medical Advisory Board and US Hereditary Angioedema Association. Stephen D. Betschel has been a speaker and\/or received advisor fees from Astria Therapeutics, BioCryst, CSL Behring, Ionis, KalVista Pharmaceuticals, Pharvaris, and Takeda; and research funding from CSL Behring and Takeda. Paula J. Busse has received research support and served on advisory boards for ADARx, Astria Therapeutics, BioCryst, CSL Behring, Intellia Therapeutics, KalVista Pharmaceuticals, and Takeda; and is a consultant for CVS Pharmacy. Aleena Banerji has received research support from Astria Therapeutics, Ionis, and Takeda; and been an advisory board member for ADARx Pharmaceuticals, Astria Therapeutics, BioCryst, BioMarin Pharmaceutical, CSL Behring, Intellia Therapeutics, KalVista Pharmaceuticals, Pharvaris, and Takeda. H. James Wedner has received research support from Astria Therapeutics, BioCryst, CSL Behring, Ionis, KalVista Pharmaceuticals, Pharming Group, Pharvaris, and Takeda; been a speaker for BioCryst, BioMarin Pharmaceutical, Blueprint Medicines, CSL Behring, KalVista Pharmaceuticals, Pharming Group, and Takeda; and consulted for ADARx Pharmaceuticals, Astria Therapeutics, BioCryst, CSL Behring, Ionis, KalVista Pharmaceuticals, Pharming Group, and Takeda. Michael Manning has been a researcher\/primary investigator and speaker\/consultant for BioCryst, BioMarin Pharmaceutical, CSL Behring, Ionis, KalVista Pharmaceuticals, Pharming Group, Pharvaris, and Takeda. Rafael H. Zaragoza-Urdaz has been or is currently a clinical investigator for KalVista Pharmaceuticals, Pharvaris, and Takeda; has received honoraria from\/been a member of a speaker\u2019s bureau for BioCryst, CSL Behring, Pharming Group, and Takeda; been an advisory board member for BioCryst, Pharming Group, Regeneron, and Takeda; and received research support from AstraZeneca, GlaxoSmithKline, KalVista Pharmaceuticals, and Takeda. John Anderson has received personal fees for steering committee, advisory board, speaker bureau, and\/or clinical research activity from BioCryst, BioMarin Pharmaceutical, CSL Behring, Cycle Pharmaceuticals, KabiCare, KalVista Pharmaceuticals, Pharming Group, Pharvaris, and Shire\/Takeda. Remi Gagnon has served as a researcher for ALK-Abell\u00f3, AstraZeneca, DBV Technologies, GlaxoSmithKline, Moderna, Novartis, Regeneron, Sanofi, and Takeda; been an advisory board member for ALK-Abell\u00f3, Bausch & Lomb, Regeneron, Sanofi Genzyme, and Takeda; and received fees for speaker bureaus from Bausch & Lomb and Novartis. Alan P. Baptist reports research support from BioCryst, Ionis, and Takeda. Daniel Soteres is an advisor for CSL Behring, Cycle Pharmaceuticals, KalVista Pharmaceuticals, and Shire\/Takeda; consultant for BioCryst, KalVista Pharmaceuticals, and Pharming Group; conducted research for BioCryst, BioMarin Pharmaceutical, Ionis, KalVista Pharmaceuticals, Pharvaris, and Shire\/Takeda; and a speaker for BioCryst, CSL Behring, Pharming Group, and Shire\/Takeda. William R. Lumry is a member of advisory boards for Astria Therapeutics, BioCryst, BioMarin Pharmaceutical, CSL Behring, Intellia Therapeutics, KalVista Pharmaceuticals, Pharvaris, and Takeda; received research grants from BioCryst, BioMarin Pharmaceutical, CSL Behring, Ionis, KalVista Pharmaceuticals, and Takeda; consulting fees from Astria Therapeutics, BioCryst, CSL Behring, Fresenius Kabi, Pharming Group, and Takeda; payments for lectures from CSL Behring, Pharming Group, and Takeda; and is an advisory board member of the US Hereditary Angioedema Association. Timothy Craig has served as a speaker and researcher for Astria Therapeutics, BioMarin Pharmaceutical, Ionis, CSL Behring, Intellia Therapeutics, KalVista Pharmaceuticals, and Takeda; researcher for Pharvaris; speaker for Grifols; consultant for Astria Therapeutics, BioCryst, BioMarin Pharmaceutical, CSL Behring, Intellia Therapeutics, Ionis, and Takeda; Director for ACARE International Hereditary Angioedema Center; and member of the Medical Advisory Board for the HAE-A. Timothy Craig is an Editorial Board member of\n                      Advances in Therapy\n                      . Timothy Craig was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Daniel Petroni reports advisory boards for Takeda and has been a research\/primary investigator for BioCryst and Takeda; he is now an employee of BioCryst. F. Ida Hsu received research support from Takeda; served on advisory boards for BioCryst, CSL Behring, KalVista Pharmaceuticals, and Takeda; was a speaker for Amgen, Pharming, and Shire\/Takeda; and is a consultant for Intellia Therapeutics. Daniel Nova Estepan and Maureen Watt are employees of Takeda Development Center Americas, Inc. and hold stock and\/or share options in Takeda Pharmaceutical Company Limited. Salom\u00e9 Juethner is an employee of Takeda Pharmaceuticals USA, Inc., and holds stock and\/or share options in Takeda Pharmaceutical Company Limited. Natalie Khutoryansky is an employee of Cytel, contracted by Takeda Development Center Americas, Inc. Bruce L. Zuraw has received consulting fees from Adverum Biotechnologies, BioCryst, CSL Behring, and Takeda.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"EMPOWER was conducted in accordance with the International Council for Harmonisation Good Clinical Practice Guidelines, ethical principles that have their origins in the Declaration of Helsinki, and other local ethical and legal requirements. The study was reviewed and approved in all study sites by a central review board (Western-Copernicus Group [WCG] Institutional Review Board) or institutions\u2019 local ethics committees (Table\u00a0\n                      \n                      in the Supplementary Material). All patients or their legally authorized representatives provided informed consent to participate in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}